Cargando…

SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). METHODS: Prospective, open-label, nonrandomized clinical trial of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Avery, Robert L., Castellarin, Alessandro A., Steinle, Nathan C., Dhoot, Dilsher S., Pieramici, Dante J., See, Robert, Couvillion, Stephen, Nasir, Ma'an A., Rabena, Melvin D., Maia, Mauricio, Van Everen, Sherri, Le, Kha, Hanley, William D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Retina 2017
Materias:	Original Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5642319/ https://www.ncbi.nlm.nih.gov/pubmed/28106709 http://dx.doi.org/10.1097/IAE.0000000000001493

Ejemplares similares

Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD
por: Avery, Robert L, et al.
Publicado: (2014)

Intravitreal aflibercept and ranibizumab for pachychoroid neovasculopathy
por: Jung, Byung Ju, et al.
Publicado: (2019)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda, Sameh Mosaad, et al.
Publicado: (2017)

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
por: Williams, Patrick D, et al.
Publicado: (2012)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa, Bernardete, et al.
Publicado: (2021)

Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema
por: Demircan, Ali, et al.
Publicado: (2018)

Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis
por: Miura, Masahiro, et al.
Publicado: (2013)

Effects of a Single Intravitreal Injection of Aflibercept and Ranibizumab on Glomeruli of Monkeys
por: Tschulakow, Alexander, et al.
Publicado: (2014)

Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema
por: Shimizu, Norihiro, et al.
Publicado: (2017)

Assessment of Patient Pain Experience During Intravitreal Ranibizumab and Aflibercept Injection
por: Bilgin, Burak, et al.
Publicado: (2019)

Intravitreal aflibercept for choroidal neovascularization secondary to angioid streaks in a non-responder to intravitreal ranibizumab
por: Makri, Olga E, et al.
Publicado: (2018)

The Effects of Intravitreal Ranibizumab, Aflibercept or Dexamethasone Implant Injections on Intraocular Pressure Changes
por: Karakurt, Yucel, et al.
Publicado: (2018)

Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant
por: Herbaut, Antoine, et al.
Publicado: (2017)

Effect of intravitreal ranibizumab and aflibercept injections on retinal nerve fiber layer thickness
por: Ahn, Jayoung, et al.
Publicado: (2021)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
por: Luksa, Dorota, et al.
Publicado: (2021)

Systemic pharmacokinetic/pharmacodynamic analysis of intravitreal aflibercept injection in patients with retinal diseases
por: Kaiser, Peter K, et al.
Publicado: (2019)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

Risk analysis for patients with arterial thromboembolic events after intravitreal ranibizumab or aflibercept injections
por: Chou, Yun-I., et al.
Publicado: (2023)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
por: Sakanishi, Yoshihito, et al.
Publicado: (2017)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
por: Urban, Beata, et al.
Publicado: (2020)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
por: Razavi, Sam, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
por: Veritti, Daniele, et al.
Publicado: (2023)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015)

Formulation Stabilization and Disaggregation of Bevacizumab, Ranibizumab and Aflibercept in Dilute Solutions
por: Giannos, Steven A., et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
por: Hirano, Takao, et al.
Publicado: (2018)

Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab
por: Yamashita, Mariko, et al.
Publicado: (2014)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Wataru, Kikushima, et al.
Publicado: (2020)

Deformation of Aflibercept and Ranibizumab Syringes Causes Variation in Intravitreal Injection Volume and Risks Retinal Tear Formation
por: Raevis, Joseph J., et al.
Publicado: (2022)

Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study
por: Kishishita, Shuta, et al.
Publicado: (2022)

Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis
por: Hernandez, Luis, et al.
Publicado: (2018)

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection
por: Fujii, Ayaka, et al.
Publicado: (2014)

Effects of Ranibizumab, Bevacizumab, and Aflibercept on Senescent Retinal Pigment Epithelial Cells
por: Chae, Jae-Byoung, et al.
Publicado: (2018)

Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab
por: Wong, James G., et al.
Publicado: (2017)

Correction: Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
por: Kikushima, Wataru, et al.
Publicado: (2020)

Comment on: Ranibizumab and aflibercept intravitreal injection for treatment naïve and refractory macular oedema in branch retinal vein occlusion
por: Elkazza, Sumeia A, et al.
Publicado: (2020)

Three year outcomes of intravitreal ranibizumab and aflibercept treatment of patients with diabetic macular edema: A comparative study
por: Akbas, Yusuf Berk, et al.
Publicado: (2023)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
por: Chujo, Shinichiro, et al.
Publicado: (2020)

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept
por: Ichiyama, Yusuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6b41laekc1aoeu7gu05lqj0qmj